Beneficial effect of an oral analog of prostacyclin on pulmonary hypertension secondary to congenital heart disease

Abstract To determine whether a newly synthesized oral analog of prostacyclin, called beraprost sodium, could cause pulmonary vasodilation, we studied its hemodynamic effect on pulmonary hypertension of children, comparing it to other vasodilatory agents, such as nitric oxide and tolazoline. We studied 20 children (mean age 24 months) having pulmonary hypertension secondary to congenital heart disease. A single oral dose of beraprost sodium resulted in an appreciable reduction of pulmonary vascular resistance (mean 34%), which was comparable to that induced by inhalation of nitric oxide and intravenous delivery of tolazoline (mean 41% and 31%, respectively). The results suggest that beraprost sodium may serve as a novel and safe vasodilator for the screening of pulmonary vasoreactivity, as well as the treatment of pulmonary hypertension in children.

[1]  T. Saji,et al.  Short-term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension. , 1996, The American journal of cardiology.

[2]  J. Deanfield,et al.  Nitric oxide is superior to prostacyclin for pulmonary hypertension after cardiac operations. , 1995, The Annals of thoracic surgery.

[3]  R. Shaddy,et al.  Pulmonary vasodilatory effects of 12 and 60 parts per million inhaled nitric oxide in children with ventricular septal defect. , 1995, The American journal of cardiology.

[4]  Jesse D. Roberts,et al.  Inhaled Nitric Oxide in Congenital Heart Disease , 1993, Circulation.

[5]  J. Deanfield,et al.  Impairment of Endothelium‐Dependent Pulmonary Artery Relaxation in Children With Congenital Heart Disease and Abnormal Pulmonary Hemodynamics , 1993, Circulation.

[6]  S. Takeo Pharmacodynamics and Clinical Studies with Beraprost Sodium, a Drug for Peripheral Vascular Disease , 1992 .

[7]  C. Wippermann,et al.  Effects of tolazoline and prostacyclin on pulmonary hypertension in infants after cardiac surgery , 1992, Critical care medicine.

[8]  D. Graham,et al.  Infectious complications among patients receiving home intravenous therapy with peripheral, central, or peripherally placed central venous catheters. , 1991, The American journal of medicine.

[9]  B. Corrin,et al.  Correlations of lung morphology, pulmonary vascular resistance, and outcome in children with congenital heart disease. , 1988, British heart journal.

[10]  A Bush,et al.  Does prostacyclin enhance the selective pulmonary vasodilator effect of oxygen in children with congenital heart disease? , 1986, Circulation.

[11]  Pollack Mm,et al.  Pulmonary artery catheterization in pediatric intensive care. , 1983 .

[12]  M. Pollack,et al.  Pulmonary artery catheterization in pediatric intensive care. , 1983, Advances in pediatrics.

[13]  R H Jones,et al.  Accuracy of Diagnosis of Coronary Artery Disease by Radionuclide Measurement of Left Ventricular Function During Rest and Exercise , 1981, Circulation.

[14]  M. Leijala,et al.  The Use of Tolazoline Hydrochloride as a Pulmonary Vasodilator in Potentially Fatal Episodes of Pulmonary Vasoconstriction After Cardiac Surgery in Children , 1981, Circulation.

[15]  C. Lafarge,et al.  The estimation of oxygen consumption. , 1970, Cardiovascular research.